R1 RCM — Q2 2023 Earnings Presentation
9 slides from R1 RCM's earnings presentation, Aug 2, 2023
Slide 1: Second Quarter 2023 Earnings Call
August 2, 2023 Second Quarter 2023 Earnings Call Exhibit 99.2
Slide 2: Forward-Looking Statements
22 Forward-Looking Statements This presentation includes information that may constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-lookin
Slide 3: Second Quarter Results and Key Themes
33 Second Quarter Results and Key Themes Second Quarter 2023 Results Note1: Adjusted EBITDA is a non-GAAP measure; refer to the Appendix for reconciliation of non-GAAP financial measures • Revenue of $560.7 million, up $168.8 million or 43.1% compared to the same period last year • GAAP net income o
Slide 4: Today's Discussion Topics: Q2 Updates
44 Today's Discussion Topics: Q2 Updates Operational Performance • Advanced technology strategy centered around intelligent automation, patient experience, and scaled analytics • Leveraged data resources to implement net new automation use cases and expand machine learning models • Added generative
Slide 5: 2Q'23 Non-GAAP Results – Q/Q and Y/Y Comparison
55 2Q'23 Non-GAAP Results – Q/Q and Y/Y Comparison ($ in millions) 2Q'23 1Q'23 2Q'22 Key change driver(s) Revenue $560.7 $545.6 $391.9 • Q/Q: Higher incentive fees and modular revenue • Y/Y: Contribution from Cloudmed and new customers Adjusted Cost of Services1 $364.5 $362.2 $280.5 • Q/Q: Relativel
Slide 6: Additional Commentary: Guidance Update, Cash Flow and Balance Sheet Highlights
66 Additional Commentary Cash Flow and Balance Sheet Highlights • Revenue of $2.255 billion to $2.275 billion • GAAP operating income of $140 million to $155 million • Adjusted EBITDA1 of $600 million to $615 million. Core operating results remain at high end of original guidance range excluding phy
Slide 7: Appendix
7 Appendix
Slide 8: Use of Non-GAAP Financial Measures
88 Use of Non-GAAP Financial Measures Reconciliation of GAAP Operating Income Guidance to Non-GAAP Adjusted EBITDA Guidance $ in millions ▪ In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company
Slide 9: 2023 2022 2023 Net income (loss) $0.3 $(20.4) $0.3 Net interest expense 32.5 6.9
99 2023 2022 2023 Net income (loss) $0.3 $(20.4) $0.3 Net interest expense 32.5 6.9 30.7 Income tax (benefit) provision (8.9) (24.5) 2.7 Depreciation and amortization expense 68.8 24.7 66.0 Share-based compensation expense 20.0 11.6 10.5 CoyCo 2 share-based compensation expense 1.9 — 1.8 Other expen